文献速递胸部肿瘤放疗

每日一次与每日两次放化疗治疗局限期小细胞肺癌:随机临床试验的荟萃分析

Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.
PubMed 文献 · Radiother Oncol · 2022-01-29

该荟萃分析纳入5项随机临床试验共1941例局限期小细胞肺癌患者,比较每日一次与每日两次放化疗的疗效与毒性。结果显示两组3年总生存期和无进展生存期的相对风险均无显著差异,常规每日一次放化疗与每日两次放化疗结局相似,而大分割放疗与更好的总生存期和无进展生存期相关。

要点

  • 每日一次与每日两次放化疗的3年总生存期和无进展生存期无显著差异。
  • 大分割放疗方案与总生存期改善相关(p=0.03)。
  • 两组≥2级肺炎和食管炎发生率无差异(p=NS)。

核心结论

  • 对于局限期小细胞肺癌,每日一次常规放化疗与每日两次放化疗的结局相似。
  • 大分割放疗与更好的总生存期和无进展生存期相关。
  • 需要额外的随机III期试验探索大分割联合全身治疗以验证这些发现。

研究设计与样本

  • 遵循PRISMA指南的系统综述与荟萃分析,纳入5项比较每日一次与每日两次放化疗的随机临床试验,共1941例患者。
  • 进行荟萃回归分析探讨分次方案、生物有效剂量、预防性颅脑照射比例、选择性淋巴结照射和放疗开始时间(第1周或第4周)的影响。

主要发现

  • 每日一次组与每日两次组3年总生存期的相对风险为0.97(95%CI 0.8-1.1,p=0.731),无进展生存期的相对风险为0.90(95%CI 0.7-1.1,p=0.20)。
  • 荟萃回归分析中,大分割放疗方案与总生存期改善相关(p=0.03)。
  • 放疗开始时间(第1周或第4周)、生物有效剂量和选择性淋巴结照射对总生存期和无进展生存期无显著影响。
  • 每日两次组与每日一次组的完全缓解率分别为40%与33%(p=0.97),部分缓解率分别为50%与57%(p=0.94),总缓解率分别为89%与93%(p=0.99)。
  • 每日一次组与每日两次组完成计划放疗的比例分别为96%与94%(p=0.66),接受≥4个化疗周期的比例均为74%(p=0.99),局部失败率分别为40%与33%(p=0.88),远处失败率均为36%(p=0.99),≥2级肺炎和食管炎发生率无差异(p=NS)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要额外的随机III期试验探索大分割联合全身治疗以验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Assess Once daily (OD) chemoradiation effectiveness for LS-SCLC compared with twice daily (BID) chemoradiation. METHODS AND MATERIALS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline, eligible randomized clinical trials (RCT) comparing OD and BID were identified on electronic databases. A meta-analysis was performed to compare overall survival (OS), progression-free survival (PFS), and toxicity. A metaregression analysis was conducted to explore the influence of fractionation, biological effective dose (BED), the proportion of patients treated with prophylactic cranial irradiation (PCI), elective nodal irradiation (ENI), and the start of radiotherapy (week 1 or week 4). RESULTS: Five RCTs with a total of 1941 patients (OD vs. BID) were included. The relative risk (RR) for OS and PFS was 0.97 (CI95% 0.8-1.1, p = 0.731) and 0.90 (CI95% 0.7-1.1, p = 0.20) at 3-years. In the metaregression analysis, hypofractionated radiotherapy schedules were associated with an improvement in overall survival (p = 0.03). The start of radiotherapy (W1 or W4), BED, and ENI had no significant effect on OS and PFS. The complete response rate partial response and overall response rate for BID vs OD were 40% vs. 33% (p = 0.97), 50% vs. 57% (p = 0.94), and 89% vs. 93% (p = 0.99). The rate of completed planned RT 96% vs. 94% (p = 0.66), and the % of ≥4 chemotherapy cycles received 74% vs. 74% (p = 0.99), did not differ between OD and BID. The local and distant failure rates were not significantly different between OD and BID 40% vs. 33% (p = 0.88) and 36% vs. 36% (p = 0.99). No difference in grade 2 or grade 3 pneumonitis and esophagitis was observed among the groups (p = NS). CONCLUSION: For LS-SCLC, OD conventional chemoradiation results in similar outcomes to BID chemoradiation. In contrast, hypofractionated radiotherapy was associated with a better OS and PFS than BID. Additional randomized phase III trials exploring hypofractionation with systemic therapy are warranted to validate our findings.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Viani GA, Gouveia AG, Matsuura FK, et al. Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials. Radiother Oncol. 2022. PMID: 35101470. doi:10.1016/j.radonc.2022.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。